Challenging Clinical Cases – A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN(®))

PURPOSE: There are limited published data regarding the use of supplemental intravitreal therapies in patients with diabetic macular edema (DME) following treatment with the 0.19 mg fluocinolone acetonide (FAc; ILUVIEN(®)) intravitreal implant. The aim of this report was to analyze five challenging...

Descripción completa

Detalles Bibliográficos
Autores principales: Pessoa, Bernardete, Melo-Beirão, João, Meireles, Angelina, Menéres, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501957/
https://www.ncbi.nlm.nih.gov/pubmed/32982484
http://dx.doi.org/10.2147/IMCRJ.S262587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501957/
https://www.ncbi.nlm.nih.gov/pubmed/32982484
http://dx.doi.org/10.2147/IMCRJ.S262587

Ejemplares similares